The Covid crash continues
Pfizer keeps declining, but it is not the only pandemic player to suffer.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Novartis’s renaissance gets off to a false start
Leqvio’s launch remains sluggish and tislelizumab looks even more like a dead end in the US.
The Wegovy wait continues
Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.